Ultrasound-Guided Core-Needle Biopsy of Suspicious Breast Lesions

1. Romania in Global Cancer Statistics 2018. Oncology Today. Available at: https://www.medichub.ro/reviste/oncolog-hematolog-ro/romania-in-global-cancer-statistics-2018-id-2019-cmsid-68.Search in Google Scholar

2. Tereanu C, Baili P, Berrino F, et al. Recent trends of cancer mortality in Romanian adults: Mortality is still increasing, although young adults do better than the middle-aged and elderly population. Eur J Cancer Prev. 2013;22:199-209.10.1097/CEJ.0b013e3283581d9022968450Search in Google Scholar

3. Gøtzsche PC, Hartling OJ, Nielsen M, Brodersen J, Jørgensen KJ. Breast screening: The facts - Or maybe not. BMJ. 2009;338:446-448.10.1136/bmj.b8619174442Search in Google Scholar

4. Cardoso F, Cataliotti L, Costa A, et al. European Breast Cancer Conference manifesto on breast centres/units. Eur J Cancer. 2017;72:244-250.10.1016/j.ejca.2016.10.02328064097Search in Google Scholar

5. Travasso C. Panel issues advice on early detection of oral, breast, and cervical cancers in India. BMJ. 2015;351:h3807.10.1136/bmj.h380726170274Search in Google Scholar

6. Britton P, Sinnatamby R. Investigation of suspected breast cancer. Br Med J. 2007;335:347-348.10.1136/bmj.39234.386470.BE194946017703045Search in Google Scholar

7. John M. Eisenberg Center for Clinical Decisions and Communications Science. Core-Needle Biopsy for Breast Abnormalities. In: Comparative Effectiveness Review Summary Guides for Clinicians. 2007. Available at: http://www.ncbi.nlm.nih.gov/pubmed/27336126.Search in Google Scholar

8. National Guideline Alliance (UK). Early and Locally Advanced Breast Cancer: Diagnosis and Management.2018. Available at: https://www.ncbi.nlm.nih.gov/books/NBK519155/.Search in Google Scholar

9. Jeibouei S, Akbari ME, Kalbasi A, et al. Personalized medicine in breast cancer : pharmacogenomics approaches. Pharmgenomics Pers Med. 2019;12:59-73.10.2147/PGPM.S167886654974731213877Search in Google Scholar

10. Chan CWH, Law BMH, So WKW, Chow KM, Waye MMY. Novel Strategies on Personalized Medicine for Breast Cancer Treatment: An Update. Int J Mol Sci. 2017;18:2324.10.3390/ijms18112423571339129140300Search in Google Scholar

11. Balic M, Thomssen C, Würstlein R, Gnant M, Harbeck N. St. Gallen/Vienna 2019: A brief summary of the consensus discussion on the optimal primary breast cancer treatment. Breast Care. 2019;14:103-110.10.1159/000499931688610831798382Search in Google Scholar

12. Morigi C. Tailored Treatments for Patients With Early Breast Cancer. ecancer. 2017;11:1-12.10.3332/ecancer.2017.732540622228491135Search in Google Scholar

13. Lakhani SR, Ellis IO, Schnitt SJ, Tan PH, van de Vijver M. WHO Classification of Tumours of the Breast. Fourth Edition, Geneva, Switzerland: WHO Press.; 2012.Search in Google Scholar

14. Who Classification of Tumours Editorial Board. Breast Tumours. Lyon (France) Internation Agency for Research on Cancer; 2019. (WHO Classification of Tumours Series, 5th Ed.; Vol. 2).Search in Google Scholar

15. Hoon Tan P, Ellis I, Allison K, et al. The 2019 WHO classification of tumours of the breast. Histopathology. 2020. [Ahead of print]Search in Google Scholar

16. Fitzgibbons PL, Connolly JL, Edgerton M, MD, Simpson MR. Protocol for the examination of specimens From patients with invasive carcinoma of the breast. Arch Pathol Lab Med. 2020. [Ahead of print]Search in Google Scholar

17. Untch M, Gerber B, Harbeck N, et al. 13th St. Gallen international breast cancer conference 2013: Primary therapy of early breast cancer evidence, controversies, consensus - Opinion of a German team of experts (Zurich 2013). Breast Care. 2013;8:221-229.10.1159/000351692372863424415975Search in Google Scholar

18. Cardoso F, Kyriakides S, Ohno S, et al. Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2019;30:1194-1220.10.1093/annonc/mdz173Search in Google Scholar

19. Jorns JM. Challenges in routine estrogen receptor, progesterone receptor, and HER2/neu evaluation. Arch Pathol Lab Med. 2019;143:1444-1449.10.5858/arpa.2019-0205-RASearch in Google Scholar

20. Fitzgibbons PL, Bartley AN, Connolly JL. Template for reporting results of biomarker testing of specimens from patients with carcinoma of the breast. Arch Pathol Lab Med. 2020. [Ahead of print]Search in Google Scholar

21. Bucure C. Luna Internațională de C onștientizare d espre Cancerul de Sân (LICCS) 1-31 Octombrie 2019 Analiza de Situație. 2019:1-16. Available at: http://insp.gov.ro/sites/cnepss/wp-content/uploads/2019/10/Analiza-desituatie.pdf.Search in Google Scholar

22. Pant K, Dutta U. Understanding and management of male breast cancer: A critical review. Med Oncol. 2008;25:294-298.10.1007/s12032-007-9034-ySearch in Google Scholar

23. Schünemann HJ, Lerda D, Quinn C, et al. Breast cancer screening and diagnosis: A synopsis of the european breast guidelines. Ann Intern Med. 2020;172:46-56.10.7326/M19-2125Search in Google Scholar

24. Güth U, Huang DJ, Huber M, et al. Tumor size and detection in breast cancer: Self-examination and clinical breast examination are at their limit. Cancer Detect Prev. 2008;32:224-228.10.1016/j.cdp.2008.04.002Search in Google Scholar

25. Shaevitch D, Taghipour S, Miller A, Montgomery N, Harvey B. Tumor size distribution of invasive breast cancers and the sensitivity of screening methods in the Canadian National Breast Screening Study. J Cancer Res Ther. 2017;13:562-569.Search in Google Scholar

26. European Comission E. Breast Cancer and Cervical Cancer Screenings.; 2017. Available at: https://ec.europa.eu/eurostat/web/products-eurostat-news/-/DDN-20200109-1.Search in Google Scholar

27. Carter CL, Allen C, Henson DE. Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer. 1989;63:181-187.10.1002/1097-0142(19890101)63:1<181::AID-CNCR2820630129>3.0.CO;2-HSearch in Google Scholar

28. Orang E, Marzony ET, Afsharfard A. Predictive role of tumor size in breast cancer with axillary lymph node involvement - can size of primary tumor be used to omit an unnecessary axillary lymph node dissection? Asian Pacific J Cancer Prev. 2013;14:717-722.Search in Google Scholar

29. Michaelson JS, Silverstein M, Sgroi D, et al. The Effect of Tumor Size and Lymph Node Status on Breast Carcinoma Lethality. Cancer. 2003;98:2133-2143.10.1002/cncr.11765Search in Google Scholar

30. Narod SA. Tumour size predicts long-term survival among women with lymph node-positive breast cancer. Curr Oncol Vol. 2012;19:249-253.10.3747/co.19.1043Search in Google Scholar

31. Laura S, Coombs NJ, Ung O, Boyages J. Tumour size as a predictor of axillary node metastases in patients with breast cancer. ANZ J Surg. 2006;76:1002-1006.10.1111/j.1445-2197.2006.03918.xSearch in Google Scholar

32. Sopik V, Narod SA. The relationship between tumour size, nodal status and distant metastases: on the origins of breast cancer. Breast Cancer Res Treat. 2018;170:647-656.10.1007/s10549-018-4796-9Search in Google Scholar

33. Rambau P, Chalya P, Manyama M, Jackson K. Pathological features of Breast Cancer seen in Northwestern Tanzania: A nine years retrospective study. BMC Res Notes. 2011;4:214.10.1186/1756-0500-4-214315583521696617Search in Google Scholar

34. Bonnier P, Romain S, Charpin C, et al. Age as a prognostic factor in breast cancer: Relationship to pathologic and biologic features. Int J Cancer. 1995;62:138-144.10.1002/ijc.29106202057622286Search in Google Scholar

35. Alieldin NH, Abo-Elazm OM, Bilal D, et al. Age at diagnosis in women with non-metastatic breast cancer: Is it related to prognosis? J Egypt Natl Canc Inst. 2014;26:23-30.Search in Google Scholar

36. Nelson H, Zakher B, Cantor A, et al. Risk Factors for Breast Cancer for Women Aged 40 to 49 Years A Systematic Review and Meta-analysis. Ann Intern Med. 2012;156:635-648.10.7326/0003-4819-156-9-201205010-00006356146722547473Search in Google Scholar

37. Brewer HR, Jones ME, Schoemaker MJ, Ashworth A, Swerdlow AJ. Family history and risk of breast cancer: an analysis accounting for family structure. Breast Cancer Res Treat. 2017;165:193-200.10.1007/s10549-017-4325-2551131328578505Search in Google Scholar

38. Rummel S, Hueman MT, Costantino N, Shriver CD, Ellsworth RE. Tumour location within the breast: Does tumour site have prognostic ability? Ecancermedicalscience. 2015;9:1-10.Search in Google Scholar

39. Kroman N, Wohlfahrt J, Mouridsen HT, Melbye M. Influence of tumor location on breast cancer prognosis. Int J Cancer. 2003;105:542-545.10.1002/ijc.1111612712447Search in Google Scholar

40. Sohn VY, Arthurs ZM, Sebesta JA, Brown TA. Primary tumor location impacts breast cancer survival. Am J Surg. 2008;195:641-644.10.1016/j.amjsurg.2007.12.03918424280Search in Google Scholar

41. Geisel J, Raghu M, Hooley R. The Role of Ultrasound in Breast Cancer Screening: The Case for and Against Ultrasound. Semin Ultrasound, CT MRI. 2018;39:25-34.10.1053/j.sult.2017.09.00629317037Search in Google Scholar

42. Jacklyn G, McGeechan K, Houssami N, Bell K, Glasziou PP, Barratt A. Overdiagnosis due to screening mammography for women aged 40 years and over. Cochrane Database Syst Rev. 2018;2018:CD013076.10.1002/14651858.CD013076Search in Google Scholar

43. HD N, A C, L H, et al. Screening for Breast Cancer: A Systematic Review to Update the 2009 U.S. Preventive Services Task Force Recommendation. In: Evidence Syntheses. Vol 124.; 2016. Available at: http://europepmc.org/abstract/med/26889531.Search in Google Scholar

44. Makki J. Diversity of breast carcinoma: Histological subtypes and clinical relevance. Clin Med Insights Pathol. 2015;8:23-31.10.4137/CPath.S31563468932626740749Search in Google Scholar

45. Klimberg VS., Rivere A. Ultrasound image-guided core biopsy of the breast. Chinese Clin Oncol. 2016;5:1-9.Search in Google Scholar

46. Julia Y.S. Tsang P and GMT. Molecular Classification of Breast Cancer. Adv Anat Pathol. 2020;27(1):27-35.10.1097/PAP.000000000000023231045583Search in Google Scholar

47. Hamza AA, Idris SA, Al-haj MB, Mohammed AA. Prognostication of breast cancer using Nottingham Prognostic Index in Sudanese patients. 2014;2:1-5.Search in Google Scholar

48. Thomas JSJ, Kerr GR, Jack WJL, et al. Histological grading of invasive breast carcinoma - A simplification of existing methods in a large conservation series with long-term follow-up. Histopathology. 2009;55:724-731.10.1111/j.1365-2559.2009.03429.x19845790Search in Google Scholar

49. Megha T, Neri A, Malagnino V, et al. Traditional and new prognosticators in breast cancer: Nottingham index, Mib-1 and estrogen receptor signaling remain the best predictors of relapse and survival in a series of 289 cases. Cancer Biol Ther. 2010;9:266-273.10.4161/cbt.9.4.1065920026902Search in Google Scholar

50. Oluogun WA, Adedokun KA, Oyenike MA, Adeyeba OA. Histological classification, grading, staging, and prognostic indexing of female breast cancer in an African population: A 10-year retrospective study. Int J Health Sci (Qassim). 2019;13:3-9.Search in Google Scholar

51. Salhia B, Tapia C, Ishak EA, et al. Molecular subtype analysis determines the association of advanced breast cancer in Egypt with favorable biology. BMC Womens Health. 2011;11:44.10.1186/1472-6874-11-44320428321961708Search in Google Scholar

52. Kermani T, Kermani I, Faham Z, Dolatkhah R. Ki-67 status in patients with primary breast cancer and its relationship with other prognostic factors. Biomed Res Ther. 2019;6(2 SE-Research articles).10.15419/bmrat.v6i2.520Search in Google Scholar

53. Kasangian AA, Gherardi G, Biagioli E, et al. The prognostic role of tumor size in early breast cancer in the era of molecular biology. PLoS One. 2017;12:e0189127.10.1371/journal.pone.0189127571850529211792Search in Google Scholar

54. Giuliano AE, Connolly JL, Edge SB, et al. Breast Cancer-Major changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017;67:290-303.10.3322/caac.2139328294295Search in Google Scholar

55. Allison KH, Hammond MEH, Dowsett M, et al. Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update. J Clin Oncol. 2020;38:1346-1366.10.1200/JCO.19.0230931928404Search in Google Scholar

56. Kuijer A, King TA. Age, molecular subtypes and local therapy decision-making. Breast. 2017;34:S70-S77.10.1016/j.breast.2017.06.03228666919Search in Google Scholar